Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
02 February 2023 - 9:29AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES EXCHANGE ACT OF 1934
For
the month of January 2023
Commission
File Number: 001-41115
GENENTA
SCIENCE S.P.A.
(Translation
of registrant’s name into English)
Via
Olgettina No. 58
20132
Milan, Italy
(Address
of Principal Executive Offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Other
Events
Entry
into Development and Manufacturing Services Agreement
Genenta
Science S.p.A. (the “Company”) is furnishing this Report on Form 6-K (this “Form 6-K”) to report that on January
20, 2023 the Company and AGC Biologics S.p.A. (“AGC Biologics”), a contract development and manufacturing organization,
have entered into a development and manufacturing services agreement (the “AGC Biologics MSA”) pursuant to which AGC Biologics
will provide lentivirus vector (“LVV”) manufacture certain of the Company’s
drug products for its ongoing clinical programs (the “Services”). The AGC Biologics MSA establishes timelines for purchase
order submissions and manufacturing date changes and cancellation. The AGC Biologics MSA also sets a timeline for the Services and for
technology transfer if required and includes customary termination provisions, allowing for termination by a party upon the other party’s
uncured material breach or upon the other party’s insolvency. The Company will render payment to AGC Biologics for each stage reached
by AGC Biologics while providing the Services to the Company.
The Company has an existing manufacturing
services agreement with Molecular Medicine S.p.A (which was subsequently acquired by AGC Biologics), dated March 6, 2019, pursuant to
which AGC Biologics has agreed to manufacture the Company’s LVV and drug product for the Company’s ongoing clinical programs.
The services provided under this existing agreement are in addition to the Services that will be provided under the AGC Biologics MSA.
The
foregoing description of the AGC Biologics MSA
does not purport to be complete and is qualified in its entirety by reference of the complete text thereof, a copy of which is filed
as exhibit 10.1 to this Form 6-K.
Exhibits
†
Portions of this exhibit (indicated with markouts) have been redacted in accordance with Item 601(b)(10)(iv).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
GENENTA
SCIENCE S.P.A. |
|
|
|
By: |
/s/
Richard B. Slansky |
|
Name: |
Richard
B. Slansky |
|
Title: |
Chief
Financial Officer |
Dated:
February 1, 2023
Genenta Science (NASDAQ:GNTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Genenta Science (NASDAQ:GNTA)
Historical Stock Chart
From Jul 2023 to Jul 2024